Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution

被引：1

作者：

Sotelo, Marta ^{[1
]}

Munoz-Unceta, Nerea ^{[1
]}

Matorras, Antonio ^{[2
]}

Jara, Pablo ^{[1
]}

Castro, Clara ^{[1
]}

Cacho, Diego ^{[1
]}

Caramelo, Belen ^{[1
]}

Azueta, Ainara ^{[3
]}

Duran, Ignacio ^{[1
,4
]}

机构：

[1] Hosp Univ Marques de Valdecilla, Med Oncol Dept, Santander, Spain

[2] Univ Cantabria, Sch Med, Santander, Spain

[3] Hosp Univ Marques de Valdecilla, Pathol Dept, Santander, Spain

[4] Inst Invest Valdecilla, IDIVAL, Santander, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2024年 / 26卷 / 03期

关键词：

Bladder cancer; Immune checkpoint inhibitors; Atezolizumab; Real-world data; BLADDER-CANCER; CARCINOMA; THERAPY; PEMBROLIZUMAB; CHEMOTHERAPY; ASSOCIATION; MULTICENTER; IMVIGOR211; SAFETY; RISK;

D O I：

10.1007/s12094-023-03288-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PurposeImmune checkpoint inhibitors (ICIs) have been incorporated in the treatment of metastatic urothelial carcinoma (mUC) upon platinum-based chemotherapy according to the positive results of large clinical trials. Nevertheless, results from unselected populations reflecting real-world data (RWD) are highly informative to the clinician. We reviewed daily clinical practice outcomes in patients with mUC who received atezolizumab in our institution.MethodsHere we evaluated the clinical activity and safety of atezolizumab in an unselected population of mUC patients who received atezolizumab between 2018 and 2022 reflecting RWD. Efficacy and safety information were retrospectively collected.ResultsA total of 63 patients were included. The mean age was 68 years and the objective response rate was 14.3%. The median progression-free survival was 3 months and the median overall survival 6 months. At 1 year, 42% of the patients were alive. ECOG (0 vs 1) and neutrophil-lymphocytes ratio < 2 at the start of ICI were positive prognostic factors that discriminated between long vs short survivors. Overall tolerance was good with no new safety signals. Five patients (17%) had treatment-related adverse events grade & GE; 2 that required corticosteroids.ConclusionIn this retrospective study, atezolizumab was an effective and tolerable treatment option for patients with mUC after progression to platinum-based chemotherapy. Yet, patient selection remains critical to improve outcomes.

引用

页码：682 / 688

页数：7

共 23 条

[1] Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up [J].

Balar, A. V. ;

Castellano, D. E. ;

Grivas, P. ;

Vaughn, D. J. ;

Powles, T. ;

Vuky, J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Necchi, A. ;

Petrylak, D. P. ;

Plimack, E. R. ;

Xu, J. Z. ;

Imai, K. ;

Moreno, B. H. ;

Bellmunt, J. ;

de Wit, R. ;

O'Donnell, P. H. .

ANNALS OF ONCOLOGY, 2023, 34 (03) :289-299

[2] SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy [J].

Bamias, A. ;

Merseburger, A. S. ;

Loriot, Y. ;

James, N. ;

Choy, E. ;

Castellano, D. ;

Lopez-Rios, F. ;

Calabro, F. ;

Kramer, M. ;

de Velasco, G. ;

Zakopoulou, R. ;

Tzannis, K. ;

Sternberg, C. N. .

ESMO OPEN, 2021, 6 (03)

[3] The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma [J].

Bedke, Jens ;

Albiges, Laurence ;

Capitanio, Umberto ;

Giles, Rachel H. ;

Hora, Milan ;

Ljungberg, Borje ;

Marconi, Lorenzo ;

Klatte, Tobias ;

Volpe, Alessandro ;

Abu-Ghanem, Yasmin ;

Dabestani, Saeed ;

Fernandez-Pello, Sergio ;

Hofmann, Fabian ;

Kuusk, Teele ;

Tahbaz, Rana ;

Powles, Thomas ;

Bex, Axel .

EUROPEAN UROLOGY, 2023, 83 (01) :10-+

[4] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].

Bellmunt, J. ;

de Wit, R. ;

Vaughn, D. J. ;

Fradet, Y. ;

Lee, J. -L. ;

Fong, L. ;

Vogelzang, N. J. ;

Climent, M. A. ;

Petrylak, D. P. ;

Choueiri, T. K. ;

Necchi, A. ;

Gerritsen, W. ;

Gurney, H. ;

Quinn, D. I. ;

Culine, S. ;

Sternberg, C. N. ;

Mai, Y. ;

Poehlein, C. H. ;

Perini, R. F. ;

Bajorin, D. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026

[5] Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis [J].

Chierigo, Francesco ;

Wenzel, Mike ;

Wuernschimmel, Christoph ;

Flammia, Rocco Simone ;

Horlemann, Benedikt ;

Tian, Zhe ;

Saad, Fred ;

Chun, Felix K. H. ;

Tilki, Derya ;

Shariat, Shahrokh F. ;

Gallucci, Michele ;

Borghesi, Marco ;

Suardi, Nazareno ;

Terrone, Carlo ;

Karakiewicz, Pierre, I .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 169

[6] Association Between Smoking and Risk of Bladder Cancer Among Men and Women [J].

Freedman, Neal D. ;

Silverman, Debra T. ;

Hollenbeck, Albert R. ;

Schatzkin, Arthur ;

Abnet, Christian C. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (07) :737-745

[7]

Galsky M, 2022, J UROLOGY, V207, DOI [10.1097/ju.0000000000002536.01, 10.1097/JU.0000000000002536.01]

[8]

iarc, WHO CANC MORTALITY D

[9] Bladder cancer [J].

Kamat, Ashish M. ;

Hahn, Noah M. ;

Efstathiou, Jason A. ;

Lerner, Seth P. ;

Malmstrom, Per-Uno ;

Choi, Woonyoung ;

Guo, Charles C. ;

Lotan, Yair ;

Kassouf, Wassim .

LANCET, 2016, 388 (10061) :2796-2810

[10] Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors [J].

Khaki, Ali Raza ;

Li, Ang ;

Diamantopoulos, Leonidas N. ;

Bilen, Mehmet A. ;

Santos, Victor ;

Esther, John ;

Morales-Barrera, Rafael ;

Devitt, Michael ;

Nelson, Ariel ;

Hoimes, Christopher J. ;

Shreck, Evan ;

Assi, Hussein ;

Gartrell, Benjamin A. ;

Sankin, Alex ;

Rodriguez-Vida, Alejo ;

Lythgoe, Mark ;

Pinato, David J. ;

Drakaki, Alexandra ;

Joshi, Monika ;

Isaacsson Velho, Pedro ;

Hahn, Noah ;

Liu, Sandy ;

Alonso Buznego, Lucia ;

Duran, Ignacio ;

Moses, Marcus ;

Jain, Jayanshu ;

Murgic, Jure ;

Baratam, Praneeth ;

Barata, Pedro ;

Tripathi, Abhishek ;

Zakharia, Yousef ;

Galsky, Matthew D. ;

Sonpavde, Guru ;

Yu, Evan Y. ;

Shankaran, Veena ;

Lyman, Gary H. ;

Grivas, Petros .

CANCER, 2020, 126 (06) :1208-1216

← 1 2 3 →